As jurisdictions such as Canada demonstrate increasing interest in providing access to psychedelic-assisted therapies, many organizations are seeking to address ways to safely and effectively meet future demand for such treatments. Here, we take a look at how Numinus is aiming to apply an implementation science approach to guide the development of the sector in a responsible way.


Previous articleMindset Pharma and InterVivo Solutions to Jointly Develop Advanced Cooperative Psychedelics Evaluation Platform (“Cope”); Cope Expected to Be World’s First in Vivo Psychedelic Benchmark Data Set
Next articlePsilocybin Data Study Agreement Reached Between Silo Wellness and Ehave Using Brain Scientific Mapping Neurocap